NOVARTIS
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 80
- Registration Number
- NCT00434317
- Locations
- 🇭🇺
Novartis Investigative Site, Szekesfehervar, Hungary
Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects
- Conditions
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2008-04-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 4400
- Registration Number
- NCT00434733
- Locations
- 🇵🇱
Centrum Badań Farmakologii Klinicznej monipol, Kraków, Poland
Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
- Conditions
- Interventions
- First Posted Date
- 2007-02-09
- Last Posted Date
- 2011-04-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 255
- Registration Number
- NCT00433017
- Locations
- 🇬🇧
Novartis Investigative site, Manchester, United Kingdom
Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density
- Conditions
- Interventions
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2011-03-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 110
- Registration Number
- NCT00431444
- Locations
- 🇺🇸
Women's Health Research, Phoenix, Arizona, United States
🇺🇸Alegent Health, Omaha, Nebraska, United States
🇺🇸UMDNJ-Robert Wood Johnson Medical Center, New Brunswick, New Jersey, United States
Safety and Efficacy of Methylphenidate in Children With Attention-deficit Hyperactivity Disorder (ADHD)
- Conditions
- Interventions
- First Posted Date
- 2007-01-30
- Last Posted Date
- 2011-05-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 150
- Registration Number
- NCT00428792
- Locations
- 🇩🇪
Novartis Investigative Site, Freiburg, Germany
Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2007-01-30
- Last Posted Date
- 2014-06-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 262
- Registration Number
- NCT00428389
- Locations
- 🇺🇸
Margolin Brain Institute, Fresno, California, United States
🇺🇸Sunrise Clinical Research, Hollywood, Florida, United States
🇺🇸Premiere Research Institute @ Palm Beach Neurology, West Palm Beach, Florida, United States
Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam
- Conditions
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 22
- Registration Number
- NCT00427505
Efficacy and Safety of Diclofenac Sodium Gel (DSG) in Knee Osteoarthritis
- Conditions
- Interventions
- First Posted Date
- 2007-01-25
- Last Posted Date
- 2007-12-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 420
- Registration Number
- NCT00426621
- Locations
- 🇺🇸
Holston Medical Group, Kingsport, Tennessee, United States
🇺🇸North Carolina Arthritis & Allergy Care Center, Raleigh, North Carolina, United States
🇺🇸Texas Research Center, LLP, Sugar Land, Texas, United States
Effects of Imatinib in Subjects With Seasonal Allergic Rhinitis and Who Are Sensitive to Timothy Grass Pollen
- Conditions
- First Posted Date
- 2007-01-24
- Last Posted Date
- 2007-11-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00426179
- Locations
- 🇬🇧
Novartis Investigative site, Horsham, United Kingdom
Effect of Severe Renal Impairment on Pharmacokinetics and Metabolism of a Single Administration of Licarbazepine
- Conditions
- First Posted Date
- 2007-01-24
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 12
- Registration Number
- NCT00426036
- Locations
- 🇨🇿
Novartis Investigative site, Prague, Czech Republic